If approved, Novartis’ remibrutinib has potential to be the first of a new class of chronic spontaneous urticaria (CSU) treatment in a decade.
Positive top-line...
Nearly 50% of the children diagnosed with neuroblastoma are considered high-risk, where the tumor has spread, making surgery no longer a viable treatment option....
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, today awarded $50.1 million to fund clinical-stage research...
Extended EU approval of Soliris to paediatric generalised myasthenia gravis (gMG) patients is based on Phase III data which demonstrated improvement in disease severity...
Xu, Y. et al. A novel controllable molecularly imprinted drug delivery system based on the photothermal effect of graphene oxide quantum dots. J. Mater....
